Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE vs FLAGYL I.V.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Intra-abdominal infections (e.g., peritonitis, abscess),Pelvic inflammatory disease,Bacterial vaginosis,Surgical prophylaxis,Anaerobic infections (e.g., Clostridium, Bacteroides),Off-label: Helicobacter pylori eradication, rosacea, Crohn's disease
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Hepatic metabolism via oxidation and glucuronidation; major metabolites: hydroxy metabolite (active) and acetic acid metabolite; CYP450 involvement primarily CYP2A6 and CYP3A4.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
90-95% bound to alpha-1-acid glycoprotein and albumin.
Less than 20%, primarily bound to albumin.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
0.5-0.8 L/kg; indicates extensive tissue distribution, including CNS, bone, and abscesses.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
Intravenous: 100%.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No dose adjustment for Cr Cl >10 m L/min. For Cr Cl <10 m L/min, extend interval to every 12 hours. For hemodialysis, administer dose post-dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75%.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Loading dose: 15 mg/kg IV. Maintenance: 7.5 mg/kg IV every 6 hours. Maximum single dose: 750 mg.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
Monitor renal function; adjust dose based on Cr Cl. No specific age-related dose reduction.
Not available.
Carcinogenicity has been observed in chronic animal studies; avoid chronic use unless necessary.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Peripheral neuropathy and central nervous system toxicity (e.g., seizures, encephalopathy) with prolonged use; discontinue if neurological symptoms appear; use with caution in hepatic impairment; may cause disulfiram-like reaction with alcohol.
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
Hypersensitivity to metronidazole or nitroimidazoles; first trimester of pregnancy; concomitant use with disulfiram or alcohol.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Avoid alcohol and any products containing ethanol (e.g., cough syrups, mouthwash) during therapy and for at least 48 hours after completion. No specific food restrictions.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Flagyl I. V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Second and third trimesters: Use only if clearly needed; no documented fetal toxicity at usual doses.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
Metronidazole is excreted in breast milk; M/P ratio approximately 0.9-1.0. Peak milk concentration 2-4 hours after dose. Breastfeeding not recommended during therapy and for 24 hours after the last dose due to potential carcinogenicity and adverse effects in infant.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
No specific dose adjustments required in pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may slightly reduce serum levels but not necessitate dose modification. Use standard adult dosing with caution in severe hepatic impairment.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
FLAGYL I. V. (metronidazole) is a nitroimidazole antibiotic with potent anaerobic coverage. It is the drug of choice for Clostridioides difficile infection, but oral vancomycin is preferred for severe cases. IV formulation is used when oral route is not feasible. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). Metronidazole can prolong QT interval; use caution with other QT-prolonging drugs. It is compatible with most IV solutions but avoid mixing with calcium-containing solutions.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, headache, and flushing.,Inform your doctor if you experience numbness or tingling in your hands or feet, as this may indicate nerve damage.,Report any new or worsening symptoms, especially if you have liver disease or are on blood thinners like warfarin (metronidazole can increase INR).,Do not take this medication if you are pregnant without consulting your doctor, especially in the first trimester.,Shake the IV bag gently before use; do not use if the solution is cloudy or contains particles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE vs FLAGYL I.V., answered by our medical review team.
ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. FLAGYL I.V. is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE and FLAGYL I.V. depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. The standard adult dose of FLAGYL I.V. is: 500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE and FLAGYL I.V. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. FLAGYL I.V. is classified as Category C. Flagyl I.V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.